Items where authors include "Corrie, P.G."

Article

Jones, R.P. orcid.org/0000-0001-5608-001X, Lee, L.Y.W., Corrie, P.G. et al. (2 more authors) (2023) Individualized cancer vaccines versus surveillance after adjuvant chemotherapy for surgically resected high-risk stage 2 and stage 3 colorectal cancer: protocol for a randomized trial. British Journal of Surgery, 110 (12). pp. 1883-1884. ISSN 0007-1323

Gomes, F., Lewis, A., Morris, R. et al. (33 more authors) (2020) The care of older cancer patients in the United Kingdom. ecancermedicalscience, 14. 1101.

Corrie, P.G., Qian, W., Basu, B. et al. (31 more authors) (2020) Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. British Journal of Cancer, 122 (12). pp. 1760-1768. ISSN 0007-0920

Corrie, P.G., Marshall, A., Nathan, P.D. et al. (36 more authors) (2018) Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Annals of Oncology, 29 (8). pp. 1843-1852.

Ahmad, S.S., Qian, W., Ellis, S. et al. (26 more authors) (2015) Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. Melanoma Research, 25 (5). pp. 432-442. ISSN 0960-8931

Proceedings Paper

Danson, S., Collinson, M., Plummer, E.R. et al. (17 more authors) (2025) Comparison of 1 year versus minimum 2 years of anti-PD1-based immunotherapy as first-line treatment for metastatic melanoma: Results of the DANTE phase III trial. In: Journal of Clinical Oncology. 2025 ASCO Annual Meeting II, 30 May - 03 Jun 2025, Chicago, USA. American Society of Clinical Oncology (ASCO) .